ArticleEuropean journal of nuclear medicine and molecular imaging2017
Article in European journal of nuclear medicine and molecular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- Genotype-dependent [European journal of nuclear medicine and molecular imaging · 2026Article
- Comparison ofRadiology. Imaging cancer · 2025Article
- LAT4 drives temozolomide induced radiotherapy resistance in glioblastoma by enhancing mTOR pathway activation.Cancer cell international · 2024Article
- Contribution of the L-Type Amino Acid Transporter Family in the Diagnosis and Treatment of Prostate Cancer.International journal of molecular sciences · 2023Review
- Overexpression of miR-375 and L-type Amino Acid Transporter 1 in Pheochromocytoma and Their Molecular and Functional Implications.International journal of molecular sciences · 2022Article
- Review
- Expression of Glutamine Metabolism-Related and Amino Acid Transporter Proteins in Adrenal Cortical Neoplasms and Pheochromocytomas.Disease markers · 2021Article
- Natural History and Management of Familial Paraganglioma Syndrome Type 1: Long-Term Data from a Large Family.Journal of clinical medicine · 2020Article
- Fluorinated phenylalanines: synthesis and pharmaceutical applications.Beilstein journal of organic chemistry · 2020Review
- Exploring the link between tumour metabolism and succinate dehydrogenase deficiency: AClinical endocrinology · 2019Article
- Characteristic CT features of pheochromocytomas - probability model calculation tool based on a multicentric study.Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia · 2019Article
- Diagnostic Investigation of Lesions Associated with Succinate Dehydrogenase Defects.Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · 2019Review
- New fluoroethyl phenylalanine analogues as potential LAT1-targeting PET tracers for glioblastoma.Scientific reports · 2019Article
- New Insights into the Nuclear Imaging Phenotypes of Cluster 1 Pheochromocytoma and Paraganglioma.Trends in endocrinology and metabolism: TEM · 2017Review
- Fluorine-18 labeled amino acids for tumor PET/CT imaging.Oncotarget · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
purposeF-FDOPA is a highly sensitive and specific radiopharmaceutical for pheochromocytoma and paraganglioma (PPGL) imaging. However,
methodsFrom 2007 to 2015, 175 patients with non-metastatic PPGL were evaluated by
resultsThe SDHx mutated samples exhibited a significant decrease in mRNA expression of LAT3 when compared to sporadic PPGLs (P = 0.042). There was also a statistical trend toward decreased CD98hc (P = 0.147) and LAT4 (P = 0.012) levels in SDHx vs sporadic PPGLs. No difference was observed for LAT1/LAT2 mRNA levels. LAT1 protein was expressed in 15 out of 16 (93.75%) SDHx tumors, regardless of the
conclusionsWe conclude that down-regulation of LAT1/CD98hc cannot explain the imaging phenotype of SDHx-related PPGLs. A reduced activity of LAT1 remains the primary hypothesis possibly due to a modification of intracellular amino acid content which may reduce
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.